ArticleRSC advances2022
A portable colorimetric chemosensing regime for ractopamine in chicken samples using μPCD decorated by silver nanoprisms.
Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Exploring the frontiers of emerging sensing of silver nanoprisms: recent progress and challenges.RSC advances · 2025Review
- A systematic review of sensors to combat crime and routes to further sensor development.Frontiers in chemistry · 2025Review
- Microfluidic paper-based colorimetric quantification of malondialdehyde using silver nanoprism towardRSC advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years the use of ractopamine (RAC), originally synthesized for the treatment of respiratory diseases, is on the rise as a dietary supplement in animals. The excessive use of RAC has some adverse effects on human health. Hence, the demand for simple, easy-to-use, and expendable devices for RAC recognition, even in remote areas, is felt more than ever before. This need prompted us to devise a straightforward colorimetric system for RAC recognition based on the etching effect of RAC on AgNPrs. This nanoprobe is a very advanced materials with great optical properties and stability, which could be used unprecedentedly without any combination or reagents for RAC recognition. Considering the needs and advantages, a simple colorimetric chemosensor for the quantification of RAC was designed and applied to a chicken sample. The designed chemosensor was integrated with an optimized microfluidic paper-based colorimetric device (μPCD), creating a suitable tool for the determination of RAC based on a time/color pattern. The analytical metrics for this simple colorimetric chemosensing regime comprise a best colorimetric LLOQ of 100 μM in solution with 10 μM of μPCD, a spectroscopic LLOQ of 10 nM, and a broad linearity range of 0.1-10 000 μM, which are outstanding compared with other colorimetric techniques. The main remarkable features of this study include the first utilization of AgNPrs with high stability and excellent optical properties without any reagent as an optical sensing probe and optimized μPCD toward RAC recognition and the innovative time/color semi-analytical recognition method. Moreover, the prepared portable μPCD modified with AgNPrs could be a prized candidate for commercialization due to the benefits of the low-cost materials used, like paper and paraffin, and the simple instructions for μPCD preparation. This report could be a pioneering work, inspiring simple and effective on-site semi-analytical recognition devices for harmful substances or illegal drugs, which simply consist of a piece of lightweight paper and one drop of the required reagent.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.